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risk and duration of hospital admissions in patients with DLB, and compare these to those in Alz-
heimer’s disease (AD) and the general population.
Methods: A large database of mental health and dementia care in South London was used to
assemble a cohort of patients diagnosed with DLB. These were 1:4 matched with patients diagnosed
with AD on age, gender, and cognitive status.
Results: Rates of hospital admissions in the year after dementia diagnosis were significantly higher in
194 patients with DLB than in 776 patients with AD (crude incidence rate ratio 1.50; 95% confidence
interval: 1.28–1.75) or the catchment population (indirectly standardized hospitalization rate 1.22; 95%
confidence interval: 1.06–1.39). Patients with DLB had on average almost four additional hospital days
per person-year than patients with AD. Multivariate Poisson regression models indicated poorer phys-
ical health early in the disease course as the main driver of this increased rate of hospitalization,
whereby neuropsychiatric symptoms additionally explained the higher number of hospital days.
Discussion: Patients with DLB are more frequently admitted to general hospitals and utilize inpatient
care to a substantially higher degree than patients with AD or the general elderly population. These data
highlight an opportunity to reduce hospital days by identifyingDLB earlier and providingmore targeted
care focused on the specific triggers for hospitalization and associations of prolonged stay.
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Hospitalization is a major cost driver in dementia [1–3]
with longer and more frequent, more potentially avoidable,
and more unplanned hospital admissions in people with
Alzheimer’s disease (AD) than the general population [3–6].
Dementia with Lewy bodies (DLB) is the second most
common type of neurodegenerative dementia [7]. Given the
complex clinical phenotypewithmotor, psychiatric, and auto-
nomic symptoms in addition to dementia, people with DLBimer’s Association. This is an open access article under the CC BY-NC-ND
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known increased risk of iatrogenic complications, functional
decline, and delirium [8–10] when frail, elderly people are
admitted to general hospitals is likely to be aggravated in
patients with DLB. Neuropsychiatric symptoms, as well as
fluctuations mimicking delirium, are frequent in DLB
[11,12] and may deteriorate in the unfamiliar general
hospital setting, increasing the likelihood of neuroleptic use
and sensitivity reactions [13]. Several studies have reported
a relatively poor prognosis inDLB, including earlier mortality
and nursing home admission [14,15] and higher health-care
costs [16,17]. Yet, hospitalization has, to our knowledge,
only been evaluated in the context of small scale analyses
focusing on economic impact [16,18,19].
Our aim was to investigate the rate, number, duration,
cost, and risk factors of hospitalization in patients with
DLB and compare these with a matched AD cohort and
the general elderly population. Such knowledge may inform
health-planners to target care and interventions to lower hos-
pitalization risk, thereby benefiting patients and caregivers
as well as reducing costs.2. Methods
2.1. Data source
Data for this study were obtained from the South London
and Maudsley NHS Foundation Trust (SLaM) Biomedical
Research Centre Clinical Record Interactive Search (CRIS)
application. SLaM is one of the Europe’s largestmental health
and dementia care providers, serving a geographic catchment
of four South London boroughs (Lambeth, Lewisham, South-
wark, and Croydon) with a population of over 1.2 million res-
idents. In 2007–2008, the CRIS application was developed
with NIHR funding to provide researchers access to anony-
mized copies of SLaM’s electronic health record within a
robust governance framework [20,21]. CRIS has received
ethical approval as an anonymized data resource (Oxford
Research Ethics Committee C, reference 08/H0606/7115),
and a number of data linkages have been set up, including to
the national hospitalization data [22] used in this analysis. In
addition to variables which can be extracted from compulsory
structured fields in the source record, a range of bespoke nat-
ural language processing algorithms using General Architec-
ture for Text Engineering software (https://gate.ac.uk) have
allowed the extraction of entities recorded in text fields
[21,23]. Development (p.4–6), performance (p.8–11), and
strengths and limitations (p.10–12) of using the General
Architecture for Text Engineering software in CRIS have
been described by Perera et al. [21].
2.2. Study cohort
We used CRIS to extract a sample of AD and DLB cases
diagnosed in SLaM services between January 1, 2006 and
March 31, 2013. Date of the first dementia diagnosis served
as index date. Diagnosis of AD was classified according tothe International Classification of Diseases, Tenth Revision
(ICD-10) codes [24]. DLB cases were identified using theGen-
eral Architecture for Text Engineering natural language pro-
cessing software [21], which extracted any text strings
associated with a diagnosis statement of Lewy body dementia
or disease.
To assess the performance of the electronic case identifica-
tion, a subset of 69 cases identified through the natural language
processing software were examined by three clinicians with an
experience of the diagnosis of DLB. In a consensus meeting
with two senior experts, the raters ascertained the “research di-
agnoses” (applying McKeith criteria [25]) of probable DLB,
possible DLB, dementia in Parkinson’s disease, or no Lewy
body disease (LBD). Of the 69 electronically identified cases,
“research diagnoses” were probable DLB (59.5%, n 5 41),
possibleDLB (18.8%, n5 13), andParkinson’s disease demen-
tia (17.4%, n5 12). Only three case records (4.3%) contained
false positives (no LBD).
WematchedDLBand randomly selectedADcases on a 1:4
ratio according to gender, age, and Mini–Mental State Exam-
ination (MMSE) [26] score categories at dementia diagnosis.
Agewas categorized in 5-year bands from55-59 to 951 years.
MMSE groups were 0–9, 10–14, 15–19, 20–24, and 25–30
score points at the time of first dementia diagnosis. DLB cases
andAD controls were only included if data on all threematch-
ing variables were available.
Population level data were acquired from the publicly
available Admitted Inpatient Care data set of the Hospital
Episode Statistics (HES) for England [22]. We were able
to ascertain the number of hospitalizations in the source pop-
ulation from 2006–2013 in the available age bands of 60–74
and 751 years. We calculated age-band specific standard-
ized admission ratios for patients with DLB and AD within
those age categories. Of note, these data sets represent the
unselected general elderly population and thereby include
people with dementia.2.3. Outcomes
General hospital admissions (excluding admissions to
psychiatric units) prior and after dementia diagnosis were
extracted from the HES data [22]. The HES database
records all admissions to all the National Health Service
hospitals in England and includes diagnoses and proced-
ures. Within the National Health Service, HES allows
tracking of patients between different hospitals and across
different years. These also allow distinction between elec-
tive (planned) and emergency (unplanned) admissions. We
extracted the primary discharge diagnosis and determined
days spent in hospital, and whether an admission was
planned or unplanned. Two analytic approaches were adop-
ted: (1) to reduce competing mortality effects, we ascer-
tained and modeled number and days of hospitalization
in a 1-year window around dementia diagnosis; (2) not
limiting follow-up, we further calculated time to first hos-
pitalization after the index date. HES data were available
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date or the date of death served as cut-off date.
To determine hospitalization costs,we extracted healthcare
resource groups (HRGs) from the HES database. Hospitals in
England are funded through a prospective payment system,
whereby payments are defined through HRGs which are allo-
cated to each patient. HRG allocation is determined by age of
the patient, primary diagnosis, procedures received (if any),
and the level of complications [27]. Payments for each HRG
are adjusted regularly, and we determined the cost incurred
by each patient in the year according to the HRG versionvalid
for the respective time period.
2.4. Covariates
Other variables extracted were demographic factors
including ethnicity, marital status, a neighborhood-level index
of socioeconomic deprivation [28], and data from the Health
of the NationOutcome Scales (HoNOS651) instrument. This
is a validated standard measure of patient well-being and
functioning used in the UK mental health services [29,30].
HoNOS651 subscales are each rated 0 (no problem) to 4
(severe or very severe problem) and to ease interpretation,
we dichotomized these subscale scores to “minor or no
problem” (0–1) and “mild to severe problems” (2–4).
Subscales included the “problems related to physical illness
and disability scale”, used in this analysis as a general
measure of physical well-being and multi-morbidity.
2.5. Statistical analysis
We used STATA 13 software (Stata Corp LP, College Sta-
tion, TX). Baseline differences between the AD and DLB
cohort were assessed using t-tests for continuous parametric
data, the Wilcoxon rank sum test for nonparametric data,
and chi-squared test for categorical variables. To compare
the number of hospitalizations in the year after dementia diag-
nosis to the general population in the catchment area, we
calculated age-specific indirectly standardized hospitalization
ratios according to age bands (60–74 and 751 years). We
further assessed the differences in planned and unplanned ad-
missions as well as hospital days between the two dementia
cohorts using fixed-effect Poisson regression models (report-
ing results as incidence rate ratios comparing rates of admis-
sion or hospital days in the DLB with the AD group) and
stratified Cox regression models. Both were adjusted for soci-
odemographic factors,mental and physical comorbidities, and
functional status. Finally, we ascertained primary (ICD-10)
discharge diagnoses grouped into disease categories,
comparing incidence rates using the mid-P exact test [31]
and corrected this analysis for multiple comparisons using
the Benjamini–Hochberg false discovery rate procedure [32].3. Results
Overall, we identified 10,159 cases with a dementia diag-
nosis during the observation period, 6300 of whom had adiagnosis of AD. We identified 200 patients diagnosed
with DLB; of these, six were excluded as no MMSE score
was recorded at the time of dementia diagnosis. The remain-
ing 194 DLB cases were matched to 776 with an AD diag-
nosis according to age, gender, and MMSE score groups.
3.1. Baseline characteristics
Characteristics of theDLBandADgroups at the time ofde-
mentia diagnosis are presented in Table 1. The groups did not
differ significantly on sociodemographic variables such as
ethnicity, deprivation score, or marital status. In addition to
the defining characteristics as hallucinations and/or delusions,
the DLB cohort had an adverse neuropsychiatric and func-
tional profile, with a significantly higher occurrence of prob-
lems due to aggression, self-injury, and depressed mood, as
well as problems with activities of daily living, occupational
and recreational activities, and social relationships. A signifi-
cantly higher percentage of patients with DLB suffered from
physical health problems on theHoNOS651 “physical illness
and disability scale” at the time of dementia diagnosis. As
demonstrated in Table 1, patientswithDLB had a higher num-
ber of hospital admissions, hospital days, and hospitalization
costs in the year before dementia diagnosis.
3.2. Hospitalization after dementia diagnosis
Mean follow-up time available for patients with DLB was
10.1 months and for patients with AD 11.3 months; 164 pa-
tients with DLB contributed 162.5 person-years follow-up
time and 776 patients with AD 733.1 person-years. In this
time period, 52.6% (102) of patients with DLB and 42.9%
(333) of patients with AD had at least one admission to a gen-
eral hospital. Mean numbers of planned and unplanned hospi-
talizations and hospital dayswithin the first year after dementia
diagnosis are presented in Table 2. Patients with DLB had
significantly more hospitalizations, unplanned admissions,
and days in hospital than their AD counterparts. No significant
differences were detected in planned admissions.
Indirectly, standardized admission ratios showed differ-
ences between the general population and the two patient
groups. The admission ratio for patients with DLB was
higher than the general population (1.22 [95% confidence in-
terval {CI}: 1.06–1.39]), whereas it was lower in the AD
cohort (0.91 [95% CI: 0.84–0.99]).
3.3. Comparison of rates of hospital admissions and
hospital days in the first year after dementia diagnosis
Unadjusted Poisson regression models for the year
following dementia diagnosis confirmed that patients with
DLB had significantly more hospital admissions, un-
planned hospitalizations, and hospital days than patients
with AD (see Table 3). However, differences in crude inci-
dence rate ratios for hospital admissions were explained
through adjusting for physical health problems at diagnosis
and previous hospitalizations. A higher count for hospital
Table 1
Demographics and baseline characteristics
Risk factors DLB cohort (n 5 194) AD cohort (n 5 776) P value*
Sociodemographic status and cognitive functiony
Mean age at dementia diagnosis (95% CI)z 79.9 (78.8–81.0) 80.3 (79.7–80.8) .560
Female gender (%)z 50.0 50.0 1.000
Nonwhite ethnicity (%) 22.2 20.9 .694
Married or cohabiting status (%) 43.1 41.4 .648
Mean index of deprivation (95% CI) 26.6 (25.0–28.1) 26.2 (25.4–27.0) .618
Mean MMSE score at diagnosis (95% CI)z 19.2 (18.3–20.1) 18.7 (18.2–19.1) .307
HoNOS651 symptoms/disorders (%)x
Overactive, aggressive behavior 38.0 17.7 ,.001
Nonaccidental self-injury 3.1 0.7 .005
Problem-drinking or drug taking 2.1 4.2 .167
Hallucinations and/or delusions 59.2 10.0 ,.001
Depressed mood 22.9 11.4 ,.001
HoNOS651 functional problems (%)x
Activities of daily living 63.4 52.3 .001
Living conditions 10.9 10.9 .973
Occupational and recreational activities 37.0 28.2 .019
Social relationships 25.0 15.1 ,.001
HoNOS651 physical illness or disability (%)x 64.1 38.1 ,.001
Hospitalization in the year before dementia diagnosis
Any hospitalization (%) 59.3 40.3 ,.001
Emergency hospitalization (%) 51.6 31.7 .009
Mean number of hospitalizations (95% CI, n 5 total number) 1.49 (1.32–1.67; n 5 289) 0.78 (0.72–0.85; n 5 606) ,.001
Mean number of emergency hospitalizations (95% CI, n 5 total number) 1.17 (1.02–1.33; n 5 226) 0.58 (0.53–0.63; n 5 448) ,.001
Mean number of days spent in hospital (95% CI, n 5 total number) 14.51 (13.98–15.06; n 5 2815) 6.58 (6.40–6.76; n 5 5104) ,.001
Mean number of £s/$s incurred due to hospitalization
(95% CI, n 5 total number)
£3290 (£2366–£4213;
n 5 £611,868)/
$4195 ($3017–$5372;
n 5 $780,217)
£1893 (£1564–£2222;
n 5 1,469,139)/
$2345 ($1995–$2834;
n 5 $1,873,357)
,.001
Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; CI, confidence interval; MMSE, Mini–Mental State Examination; HoNOS651,
Health of the Nation Outcome Scales.
*t-test (age), Wilcoxon rank sum (MMSE, index of deprivation), or c2 test (categorical variables).
yAt the time of index dementia diagnosis.
zCohorts matched on categories of these variables.
xWhether problem present at dementia diagnosis.
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models were adjusted for sociodemographic factors and
HoNOS651 mental health and functional problem scores
in addition to accounting for physical illness. This reversed
direction of association was only present when the HoN-
OS651 “hallucinations and/or delusions” subscale was
included in the model, and the strongest effect was detected
in a Poisson regression model adjusting solely for physical
illness score, previous hospitalization, and the HoNOS651
“hallucinations and delusions” subscale (incidence rate
ratio 5 0.81; 95% CI 0.75–0.87).Table 2
Number of admissions and hospital days in the year after dementia diagnosis in D
Outcome
Mean number of admissions per person-year (95
n 5 total number of admissions)
DLB AD
All hospital admissions/days 1.31 (1.14–1.50; n 5 213) 0.86 (0.80–0.93; n
Planned admissions 0.29 (0.22–0.38; n 5 47) 0.20 (0.17–0.23; n
Unplanned admissions 1.02 (0.87–1.19; n 5 166) 0.67 (0.61–0.73; n
Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; C3.4. Assessment of time to first hospitalization after
dementia diagnosis
Mean time to first hospitalization after dementia diagnosis
was 0.89 (standard deviation 1.15) years in theDLBgroup and
1.67 (standard deviation 1.62) years in the AD group.Kaplan–
Meier curves illustrating time to first hospitalization after de-
mentia diagnosis are presented in Figure 1. A higher risk of
hospitalization in the DLB group was confirmed by the log-
rank test (log-rank c2 5 32.34, P , .001). An unadjusted
fixed-effects Cox regression model showed a 76% increased
hazard of hospitalization in DLB compared with AD. AfterLB and AD cohorts
% CIs; Mean number of hospital days per person-year (95% CIs;
n 5 total number of hospital days)
DLB AD
5 634) 10.80 (10.30–11.31; n 5 1755) 6.92 (6.73–7.11; n 5 5073)
5 145)
5 489)
I, confidence interval.
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lems, this association was attenuated to 46%, but remained
significant. Further adjustments for sociodemographic factors,
mental health, and functional problems did not substantially
affect the strength of the association (see Table 3).3.5. Discharge diagnoses coded following admissions
The most common primary discharge diagnoses were
grouped into disease categories, and numbers of hospital ad-
missions due to these categories are presented in Table 4.
The two most common causes of admissions in both groups
were infections and falls/fractures, followed by circulatory
disease. Using the Mid-P exact test to compare incidence
rates between groups, infections, dementia, anemia, and Par-
kinson’s disease were significantly more often recorded as
primary causes of admission in the DLB group. After adjust-
ing for multiple comparisons, only infections (P5 .012) and
dementia (P 5 .012) remained significant. No differences
were detected, for example, in falls/fractures, circulatory
illness or ICD-10 codes indicating autonomic dysfunction.3.6. Hospitalization costs in the first year after dementia
diagnosis
Based on HRGs assigned to patients during their hospital
stays, patients with DLB incurred hospitalization costs of
£2896 (95% CI £2887–£2904)/$3692 (95% CI $3681–
$3703) per person-year and patients with AD £2453 (95%
CI £2450–£2457)/$3128 (95% CI $3124–$3133).4. Discussion
Patients with DLB were more frequently admitted to
acute hospitals than the general population. During the
year before and after dementia diagnosis, patients with
DLB had more frequent and longer hospitalizations than pa-
tients with AD, which seemed to be driven by poor physical
health and neuropsychiatric symptoms. While patients with
DLB had almost four hospital days more per person-yearFig. 1. Kaplan–Meier curve illustrating time to first hospitalization after de-
mentia diagnosis.
Table 4
Primary discharge diagnoses
Primary cause of admission ICD-10 codes used
DLB AD
P value* Corrected P valuey
Percentage of total
hospital admissions
(total 5 213)
(n 5 number
of admissions due to
specific cause)
Percentage of total
hospital admissions
(total 5 634)
(n 5 number
of admissions due to
specific cause)
Infections A41, A48, J18, J22, J44, J69, L03, N30, N39 23.0% (n 5 49) 19.9% (n 5 126) .001 .012
Falls and fall-related injuries R55, S00, S01, S02, S09, S52, S62, S72 7.0% (n 5 15) 10.1% (n 5 64) .825 .900
Circulatory illness I20, I21, I25, I44, I47, I48, I49, I50, R00, R07 6.6% (n 5 14) 6.5% (n 5 41) .174 .261
Dementia F01, F03, G30, G31, R41 6.1% (n 5 13) 2.7% (n 5 17) .002 .012
Senility and disorientation R41, R54 5.2% (n 5 11) 4.7% (n 5 30) .166 .261
Stroke and TIA G45, I61, I63, I64, I67 3.8% (n 5 8) 2.5% (n 5 16) .075 .178
Cancer C18, C25, C34, C44, C50, C54, C61, C67,
C78, C79, C92, D07
3.3% (n 5 7) 5.1% (n 5 32) 1.000 1.000
Cataract H25, H26 3.3% (n 5 7) 3.6% (n 5 23) .459 .551
Autonomic dysfunction I95, K59, R33, R42 3.3% (n 5 7) 3.5% (n 5 22) .406 .541
Anemia D50, D51, D52, D64 3.3% (n 5 7) 1.4% (n 5 9) .020 .060
Parkinson’s Disease G20 1.9% (n 5 4) 0.3% (n 5 2) .013 .052
Delirium F05 1.4% (n 5 3) 0.5% (n 5 3) .089 .178
NOTE. Bold text indicates P , .05
Abbreviations: ICD-10, International Classification of Diseases, Tenth Revision; DLB, dementia with Lewy bodies; AD, Alzheimer’s disease.
*Comparison of incidence rates (number of hospitalizations per person-year) using the Mid-P exact test.
yP value corrected for multiple comparisons using the Benjamini–Hochberg procedure.
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reversed when the presence/severity of hallucinations and/
or delusions was included in the regression model.
Main discharge diagnoses were infections and falls/frac-
tures in both groups. On average, patients with DLB
incurred more than £400/$550 in hospitalization costs
compared to patients with AD in the year after dementia
diagnosis.
Despite the relatively high prevalence [7] and poor
prognosis of DLB, the condition has only attracted a frac-
tion of dementia research funding [12]. DLB is underdiag-
nosed in the UK, US, and other high-income countries,
and there is a lack of specialist services for this high-
risk patient group [12,13,33]. Our study suggests that
the estimated 80,000 people with DLB in the UK will
have an excess of more than 27,000 hospitalizations,
spend over 300,000 days more in hospital, and incur
more than £35 million/$45 million additional
hospitalization costs in a single year than the same
number of patients with AD. It is possible that improved
diagnosis, more careful monitoring, better information
for patients, caregivers, and the primary care health
system, combined with assertive management of the
cognitive, psychiatric, and physical symptoms according
to recently updated guidelines [34] may substantially
reduce the risk and duration of hospitalizations in these
patients. This would benefit patients, their families and
could lead to substantial cost savings but needs to be
demonstrated in carefully designed studies using complex
interventions. Some of these are already on-going, as theDIAMOND-Lewy research programme, which aims to
improve recognition and proactive management of Lewy
body dementias through development and implementation
of assessment and management toolkits [35,36], and the
Study of HAllucinations in Parkinson’s disease, Eye
disease, and Dementia, which specifically targets visual
hallucinations, their longitudinal effects on patients and
caregivers, and aims pilot management strategies for
these symptoms [37]. However, it is likely that improved
diagnosis and management will come with added costs.
For example, in patients with possible DLB, who are pre-
senting with only one of the four core features, establish-
ing a correct subtype diagnosis relies on costly biomarkers
as scans measuring dopamine uptake, myocardial scintig-
raphy, or polysomnography to detect rapid eye movement
(REM) sleep behavior disorder [34]. It nevertheless ap-
pears reasonable to believe that complex interventions,
as providing a more holistic support for patients with
DLB, can reduce hospitalization and thus offset the added
costs related to these diagnostic procedures. One likely
benefit of having an established diagnosis that can be
concluded directly from this analysis is that a more
DLB-focused approach to hallucinations can reduce the
length of stay. Although there are yet no robust evidence
for how hallucinations in DLB can be treated, there is
some indication that cholinesterase inhibitors may be
beneficial [34,38]. Clozapine [39] or pimavanserin [40],
which have proven efficacy for psychotic symptoms and
tolerability in Parkinson’s disease, may be useful in pa-
tients with DLB. Of note, it is important to avoid
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syndrome [41] or at least restrict the use to only severely
ill patients, with low dosage and in short periods. In addi-
tion, more assertive input from liaison psychiatry services
for general hospitals may potentially reduce the duration
of stay. Again, these hypotheses need to be tested in sys-
tematic trials.
Previous studies examining rates of hospitalization after
diagnosis of DLB are scarce, with small sample sizes
[16,18], and hospital admission has only been one of
several cofactors in economic analyses. A US economic
evaluation found that patients with DLB had an average
10.3 days of hospital care per year, which was
significantly higher than 1.6 days of hospital care per year
in the AD control group [18]. In contrast, a Scandinavian
study found that patients with AD used more inpatient
care (6.1 vs. 4.1 hospital days per year) [16]. In a 5-year
follow-up study, patients with DLB discontinued to visit a
Japanese memory clinic significantly more often due to hos-
pitalization or death than patients with AD (30% vs. 14%)
[19]. Our study is able to provide more detail, and to our
knowledge, we assembled one of the largest samples of pa-
tients with DLB drawn from a single-dementia assessment
and treatment provider. Furthermore, the use of national hos-
pitalization statistics guarantees near-complete outcome
data, and in regression models, we were able to adjust for
a range of potential clinical, social, and demographic con-
founders.
Although general patterns of increased hospitalization in
dementia have consistently been reported from several coun-
tries with varying systems of health-care organization and
financing, the exact numbers of bed days vary widely be-
tween studies, from 22 to 25 days per person-year in AD
in Finland [2] to 13.8 in the US [42] or 10.7 in Taiwan
[43]. In our AD cohort, admission rates and bed days
(6.9 days per person-year) were lower than in US and
Finnish data [6,44], and the indirectly standardized
admission ratios were slightly lower than the general
elderly population in our catchment area. One explanation
is that the unselected general population sample used in
our analysis included people suffering from dementia,
including DLB, while the aforementioned studies had
compared patients with AD with cognitively healthy
controls. It might further reflect a higher threshold for
hospital admission in the UK or a greater focus on
outpatient care in the UK health-care system. The higher
number of bed days in the DLB cohort further highlights
the increased use of scarce resource in this group.
As reported in previous studies [5,19,44], infections
were the most frequently reported causes of admission,
both in the AD and DLB cohort. Similar to our study,
one Japanese study [19] found that infections, particularly
bronchopneumonia, were more common causes for hospi-
talization in patients with DLB than AD. This might berelated to the lower level of functioning and higher sup-
port needs in patients with DLB earlier in the disease
course [17]. Surprisingly, the occurrence of falls and
fall-related injuries didn’t differ between the groups,
given that these are a supportive clinical feature of DLB
[25]. We were not able to determine the nature of the falls,
although a Swedish study [45] also showed no difference
in hospitalization due to syncope between the two demen-
tia subtypes. Behavioral/neuropsychiatric symptoms have
been reported as leading causes for hospitalization in AD
[46] and as increased in patients with DLB [11,12]
potentially underlying our observed increased frequency
of dementia recorded as the primary discharge diagnosis
in DLB; furthermore, while the presence of
hallucinations and/or delusions did not significantly
affect the risk of hospitalization, it explained the higher
number of days spent in hospital in patients with DLB.
In our study, the limitations of using routine electronic
health record data need to be considered. Diagnoses of de-
mentia are clinical and not autopsy confirmed, and a consid-
erable proportion of DLB cases are likely to be undetected or
classified as AD. Furthermore, patients with ADmight suffer
from other or additional pathologies. Conversely, 19% of our
test cases with a clinician diagnosis of DLB were classified
as “possible DLB” by expert raters. Although this is partly
due to incomplete recording of symptomatology in the elec-
tronic records, some of these patients might not suffer from
LBD at autopsy. Most “possible DLB” cases without DLB
will have AD, and thus the inclusion of such cases is likely
to reduce the difference between AD and DLB. Overall,
although exact estimates need to be treated with caution,
we are more likely to underestimate rather than to overesti-
mate the burden of DLB. Furthermore, a clear distinction be-
tween DLB and dementia in Parkinson’s disease was not
always possible; however, the two conditions share the
same underlying pathology, and once dementia develops,
there are no clinical or biological markers to reliably differ-
entiate the two Lewy body dementias [25]. Importantly, ours
was an observational study, and although following match-
ing no significant differences in demographics persisted in
the two cohorts, residual confounding can never be fully
excluded.
Physical health was captured through the HoNOS651
physical illness and disability subscale. Although the scale
is widely used as a routine measure of clinical outcome in
mental health and dementia services in the UK [30] and
has been shown to be a reliable predictor of mortality [47],
it is relatively brief without details on the specific
conditions determining its score. Furthermore,
hospitalization data, captured from HES [22], describes
the reason for hospitalization through an ICD-10 code re-
corded at discharge and cannot always accurately explain
why the individual admission occurred. For example, a diag-
nosis of dementia might refer to an episode of worsening
C. Mueller et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 143-152150neuropsychiatric symptoms but could also be related to a
general deterioration in health or social circumstances.
Although it is well established that the underlying neuro-
degenerative process begins years before a formal dementia
diagnosis is made [48], data on hospitalization before de-
mentia diagnosis needs to be evaluated with caution. Only
patients surviving until a dementia diagnosis will be able
to enter the cohort and this immortal time bias limits the
generalizability of predementia diagnosis estimates pre-
sented in the baseline demographics section.
Data were collected from the UK mental health and de-
mentia services as well as general hospitals over a time-
span of 7 years from 2006 to 2013. Although the diagnostic
criteria for DLB [25] have not altered over this period,
changes have taken place to the way dementia and inpatient
care is delivered in the UK, which might affect our results.
We have excluded psychiatric hospital admissions because
inpatient psychiatric for the elderly care varies substan-
tially between different regions in the UK and has under-
gone considerable structural changes in the studied
period. A sizeable reduction of psychiatric inpatient beds
has led to inpatient care only being provided to those
with highest complexity [49]. Although our results should
be a representative of the source population in South East
London, generalizations to other systems of health-care de-
livery, particularly beyond the UK context, cannot readily
be made.
To overcome some of these limitations, a prospective
study design could be used. Improved diagnostic criteria
[34] and increased awareness of DLB could improve
recruitment into prospective cohorts. Furthermore, recently,
several consortia, as the pan-European consortium on DLB
[50] or the Dementia with Lewy Bodies Consortium in the
US [51], have formed to collect data on larger scale multi-
center samples. There is also an increasing literature on
the prodromal stages in DLB [52] with delirium being pro-
posed as a presenting feature of DLB [53]. Trials could eval-
uate if more proactive identification of DLB in patients
admitted to general hospitals with delirium can lead to
improved long-term outcomes.
To conclude, we report increased and prolonged admis-
sions to general hospitals in DLB and suggest that trials
with complex interventions, involving specialized services
with input from differing medical specialties (neurology,
geriatrics, and psychiatry) and specific case management,
should be conducted to test whether hospitalizations in
DLB can be reduced.Acknowledgments
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Health.RESEARCH IN CONTEXT
1. Systematic review: We reviewed the literature using
PubMed and further examined references from the
identified studies. Several studies have investigated
rates, duration, and cost implications of hospitaliza-
tion in patients with Alzheimer’s disease. Despite de-
mentia with Lewy bodies being the second most
common form of neurodegenerative dementia, hospi-
talization has only been evaluated as one of several
outcomes in small economic studies.
2. Interpretation: We found that patients with dementia
with Lewy bodies are more frequently admitted to
general hospitals, have a longer length of stay, and
generate higher costs than patients with Alzheimer’s
disease. Main trigger for hospitalization appears to
be poor physical health, while length of stay seems
to be determined by the presence of neuropsychiatric
symptoms.
3. Future research: Further investigation is needed to
identify interventions to address triggers for hospital-
ization early and to develop strategies to reduce stay.References
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